Please assess the completion status of the following clinical trial:

Trial Title: Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Criteria for documented hyperglycemia (at least 1 must be met):~   * Clinical diagnosis of type 1 diabetes (C-peptide levels and antibody determinations are not required)~  * The diagnosis of type 1 diabetes is based on the investigator's judgment~2. Criteria for requiring insulin at diagnosis (both criteria must be met):~   * Daily insulin therapy for ≥ 6 months~  * Insulin pump therapy for ≥ 3 months (note: must be willing to disable any glucose suspend, predictive suspend, or artificial pancreas functionality on insulin pump during study)~3. Virginia camp: age 13-18 years; Colorado/Stanford camps: 6-12 years~4. Avoidance of acetaminophen-containing medications (i.e. Tylenol) while wearing the continuous glucose monitor.~5. Willingness to wear a continuous glucose sensor and physiological monitor for the duration of the study~6. Not being pregnant at the start of the trial. All female subjects of childbearing potential will be screened for pregnancy.~8. If the participant is less than 13 years of age and the parents or the study team request it, at least one parent commit to stay with the study subject at the camp site 9. A parent/caregiver is available for system training and will commit to be the main responsible person for the use of the AP system at home~Exclusion Criteria:~1. Diabetic ketoacidosis in the past 6 months~2. Hypoglycemic seizure or loss of consciousness in the past 6 months~3. History of seizure disorder (except for hypoglycemic seizure)~4. History of any heart disease including coronary artery disease, heart failure, or arrhythmias~5. History of altitude sickness~6. Chronic pulmonary conditions that could impair oxygenation~7. Cystic fibrosis~8. Current use of oral glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.~9. History of ongoing renal disease (other than microalbuminuria).~10. Subjects requiring intermediate or long-acting insulin (such as NPH, Detemir or Glargine).~11. Subjects requiring other anti-diabetic medications other than insulin (oral or injectable).~12. Pregnancy~13. Presence of a febrile illness within 24 hours of start ski camp or acetaminophen use while wearing the CGM. The camp study subject will not participate in the trial if these conditions are met.~14. Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as (for parent and/or child):~    * Inpatient psychiatric treatment in the past 6 months~   * Uncontrolled adrenal insufficiency~   * Alcohol abuse

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Artificial Pancreas Therapy (Type: EXPERIMENTAL): Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
- Sensor Augmented Pump Therapy (Type: PLACEBO_COMPARATOR): Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete